Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACDC-RP: Cabazitaxel Neoadjuvant in Prostate Cancer
NCT02543255Phase 2Completed
- Sponsor
- University Health Network
- Start
- Sep 2016
- Primary completion
- May 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabazitaxel ginsenoside liposome injection in prostate cancer (PCa), sponsored by University Health Network. Started Sep 2016; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02543255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543255.